Showing 97–108 of 192 resultsSorted by latest
Pharma & Biotech
Dr.Reddy’s Laboratories (REDY) and Nestle Health Science Limited entered a partnership in August 2024 to focus on nutraceutical products and supplements in India and Nepal, with 49% of the shares in the new subsidiary transferred to Nestle India.
Edwards Lifesciences is a company that specializes in heart valves, hemodynamic monitoring, and structural
heart solutions.
The Medicare Advantage market is facing challenges due to factors like elevated medical costs, changes in SARS ratings, and a reset of risk-adjusted revenue streams, leading to operational disruption for some.
In September, Dupixent was approved by the FDA and Chinese regulators for patients with uncontrolled COPD and an eosinophilic phenotype.
AbbVie has completed the acquisition of Cerevel Therapeutics to boost its neuroscience research, helping patients with Parkinson’s and schizophrenia.
Eli Lilly (LLY) received FDA approval for Ebglys as a first-line treatment for moderate-to-severe atopic dermatitis in adults and children aged 12 and older.
NVS remains confident in the growth of its products up to the Loss of Exclusivity (LoE).
Pfizer is focusing on areas where it has scientific leadership and can address significant patient needs.
Roche is based in Basel, Switzerland, specializing in pharmaceuticals and diagnostics.
NetScout’s advancing cybersecurity capabilities and addressing the evolving threat landscape.
In September 2024, Hurricane Helene caused significant rain and flooding in Western North Carolina, damaging assets and disrupting operations at Baxter’s North Cove facility in Marion, N.C.
Amgen continues to perform well with strong growth in oncology, rare diseases, and inflammation. Drugs like Repatha, EVENITY, TEZSPIRE, and TEPEZZA are expanding their market reach, and new biosimilars, such as PAVBLU, WEZLANA, and BEKEMV, will further strengthen their position